Mereo BioPharma Group PLC ADR (MREO)

NASDAQ
1.600
-0.070(-4.19%)
After Hours
1.600
0.000(0.006%)
- Real-time Data
  • Volume:
    1,333,339
  • Bid/Ask:
    1.600/1.620
  • Day's Range:
    1.555 - 1.680

MREO Overview

Prev. Close
1.67
Day's Range
1.555-1.68
Revenue
-
Open
1.67
52 wk Range
1.555-4.71
EPS
-7.4
Volume
1,333,339
Market Cap
173.85M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
858,959
P/E Ratio
-
Beta
-
1-Year Change
-23.44%
Shares Outstanding
108,654,596
Next Earnings Date
-
What is your sentiment on Mereo BioPharma Group PLC ADR?
or
Market is currently closed. Voting is open during market hours.

Mereo BioPharma Group PLC ADR Company Profile

Employees
38

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyBuyStrong SellStrong SellStrong Sell
SummaryStrong BuyNeutralStrong SellStrong SellStrong Sell
  • https://pulse2.com/mereo-biopharma-stock-price-nasdaq-mreo-10-target-by-needham/
    0
    • https://pulse2.com/mereo-biopharma-stock-price-nasdaq-mreo-10-target-by-needham/
      0
      • hello guys, what is new with MREO? Any updates or tp please?
        0
        • Awesome news💰👊
          0
          • Is it still a good buy at 3.8?
            0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.